WuXi PharmaTech (Cayman) (WX) Q2 2012 Earnings Call August 14, 2012 8:00 am ET Executives Ronald Aldridge - Director of Investor Relations Ge Li - Co-Founder, Chairman, Chief Executive Officer, Member of Strategy Committee and Member of Compensation Committee Edward Hu - Chief Financial Officer and Chief Operating Officer Analysts Ingrid Yin - Oppenheimer & Co. Inc., Research Division Ramesh C. Donthamsetty - JP Morgan Chase & Co, Research Division David H. Windley - Jefferies & Company, Inc., Research Division Roberto Fatta Timothy C. Evans - Wells Fargo Securities, LLC, Research Division Katherine Lu - Cowen and Company, LLC, Research Division Bin Li - Morgan Stanley, Research Division B. Kemp Dolliver - Religare Capital Markets, Research Division Hao Zhou - Piper Jaffray Companies, Research Division Shaojing Tong - BofA Merrill Lynch, Research Division Wei Du - Goldman Sachs Group Inc., Research Division Jack Hu - Deutsche Bank AG, Research Division PresentationOperator
Ladies and gentlemen, thank you for standing by and welcome to the WuXi PharmaTech Second Quarter 2012 Earnings Conference Call. [Operator Instructions] I must advise you that this conference is being recorded today, 14th of August, 2012. I would now like to hand the conference over to your speaker for today, Mr. Ron Aldridge. Sir, please go ahead. Ronald Aldridge Thank you, Jorge, and good morning or good evening, to everyone participating in our second quarter 2012 earnings conference call. Hosting this conference call today is Dr. Ge Li, Chairman and Chief Executive Officer. Joining him is Edward Hu, our Chief Financial Officer. During today's presentation and question-and-answer session, we will make forward-looking statements. These forward-looking statements represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and partially are completely outside our control. I would also like you to refer to the risk factors inherent in our business that you see here and that have been filed with the SEC and are on our company website under the Investor Relations section. Actual results can be materially different from any forward-looking statements we make today.